Item no. |
HY-120801A-1mg |
Manufacturer |
MedChem Express
|
CASRN |
1270084-92-8 |
Amount |
1mg |
Quantity options |
100 mg
10mM/1mL
10 mg
1mg
25 mg
50 mg
5 mg
|
Category |
|
Type |
Inhibitors |
Specific against |
other |
Purity |
98.11 |
Citations |
[1]Kwon G, et al. A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis. Oncotarget. 2017 Jun 16;8(43):74217-74232.<br/>[2]Cha JJ, et al. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest. 2017 Apr;97(4):419-431. |
Smiles |
OC1=C(CCC)C(C2=CC=CC=C2)=NN1C3=NC=CC=C3 |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
Ewha-18278 (free base); Isuzinaxib (free base) |
Available |
|
Product Description |
APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base effectively prevents kidney injury[1]. |
StorageTemperature |
-20°C, 3 years; 4°C, 2 years (Powder) |
Shipping |
Room Temperature |
Manufacturers Applications |
Neuroscience-Neuromodulation |
MolecularWeight |
279.34 |
Clinical Information |
Phase 2 |
Manufacturers Research Area |
Endocrinology; Inflammation/Immunology |
Solubility |
DMSO : 250 mg/mL (ultrasonic) |
Target |
NADPH Oxidase |
Manufacturers Target |
NADPH Oxidase |
Isoform |
NOX1; NOX2; NOX4 |
Manufacturers Pathway |
Metabolic Enzyme/Protease |
Manufacturers Product type |
Reference compound |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.